Research Trends

  Antisense oligonucleotides are short, engineered, single-abandoned oligodeoxynucleotides that hybridize to an objective RNA in a succession explicit way. These engineered DNA oligomers discover application in antisense treatment for the therapy of malignant growth, infection contaminations, and fiery sicknesses. A significant advantage of antisense oligonucleotides-interceded treatments is their capacity to focus on the wellspring of the pathogenesis, which builds the result of the treatment. Such advantages have provoked endorsement of these treatments in the U.S. for the treatment of infections, for example, Duchenne solid dystrophy and spinal strong decay. Other affirmed conditions incorporate, Batten sickness, cytomegalovirus retinitis, familial chylomicronaemia disorder, familial hypercholesterolemia, and innate transthyretin-intervened amyloidosis. As of late, development of Covid-19 has prompted R&D in planning antisense oligonucleotide gapmers to divide the RNA and dist

  Antisense oligonucleotides are short, synthetic, single-stranded oligodeoxynucleotides that hybridize to a target RNA in a sequence-specific manner. These synthetic DNA oligomers find application in antisense therapy for the treatment of cancer, virus infections, and inflammatory diseases. A major benefit of antisense oligonucleotides-mediated therapies is their ability to target the source of the pathogenesis, which increases the outcome of the treatment. Such benefits have prompted approval of these therapies in the U.S. for the treatment of diseases such as Duchenne muscular dystrophy and spinal muscular atrophy. Other approved conditions include, Batten disease, cytomegalovirus retinitis, familial chylomicronaemia syndrome, familial hypercholesterolemia, and hereditary transthyretin-mediated amyloidosis. Recently, emergence of Covid-19 has led to R&D in designing antisense oligonucleotide gapmers to cleave the RNA and disrupt virus replication. This can be attributed to hig